Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Ähnliche Einträge

• Prognosis After Discontinued Treatment due to Immune‐Related Adverse Events in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
  von: Hiromasa Ishihara, et al.
  Veröffentlicht: (2025)
• Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4 /6 Pathway
  von: Joo‐Hwan Park, et al.
  Veröffentlicht: (2026)
• First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study
  von: Alizée Simon, et al.
  Veröffentlicht: (2025)
• Correction to “Snail Controls the Mesenchymal Phenotype and Drives Erlotinib Resistance in Oral Epithelial and Head and Neck Squamous Cell Carcinoma Cells”
  Veröffentlicht: (2024)
• Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early‐Stage Squamous Cell Carcinoma of the Head and Neck: Long‐Term Follow‐Up
  von: Pauline Kim, et al.
  Veröffentlicht: (2025)